Intravenous Immunoglobulin Market (Indication: Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia, and Others) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Intravenous Immunoglobulin market size was estimated at USD 11.9 billion in 2021 and is expected to surpass around USD 21.7 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.3% during the forecast period 2022 to 2030.

Overview of Intravenous Immunoglobulin Market

Immunoglobulins are highly purified, sterile-specific medical therapy solutions containing gamma globulin G (IgG) in a concentration of 95% or more. These are manufactured from a highly refined pool of human plasma collected from at least 100 donors or more. Immunoglobulins can be administered through three different routes such as intramuscular, intravenous, and subcutaneous. The intramuscular route of administration is a relatively older method and is not preferred presently, as it is painful. Intravenous immunoglobulin has emerged as a boon in the last few decades for patients with compromised immune systems.

Report Scope of the Intravenous Immunoglobulin Market

Rise in R&D Activities in Intravenous Immunoglobulin To Fuel Market Growth

Increasing adoption of immunoglobulin, along with a surge in frequency of product launches and prompt approval from government regulatory bodies across the world is expected to fuel the demand during the forecast period.  According to an October 2020 update by the National Institutes of Health, a clinical trial to test the safety, tolerability, and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral Remdesivir plus, a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, was initiated in 2020. The study was performed on hospitalized adults with COVID-19 in the U.S., Mexico, and 16 other countries on five continents.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and funded the phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC. The antibody solution that was tested in the ITAC trial is anti-coronavirus hyperimmune intravenous immunoglobulin or hIVIG. Moreover, the rise in the number of government initiatives supporting the usage of the intravenous mode of delivery for some medications propels the global market. For instance, in June 2021, the Ministry of Health and Family Welfare of Karnataka, India, decided to procure an intravenous immunoglobulin (IVIG) drug worth more than INR 10 Cr for emergency use among children.

Surge in incidence of Primary Immunodeficiency Diseases to Drive Global Market

In terms of indication, the global intravenous immunoglobulin market has been classified into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. The hypogammaglobinemia segment dominated the global market in 2021. This can be attributed to increase in incidence of primary immunodeficiency diseases (PID) across the globe. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs).

Preference for Hospital Treatment to Propel Demand for Intravenous Immunoglobulin in Hospitals

Based on end-user, the global intravenous immunoglobulin market has been divided into hospitals, clinics, and home care. The hospitals segment dominated the global intravenous immunoglobulin market in 2021, owing to rise in the number of patients opting for hospital treatment rather than standalone clinics. Moreover, patients receiving IVIG infusions at home have improved quality of life, as they get better control over day-to-day activities. For instance, IVIG infusions at home care have reduced scheduling clashes for patients.

COVID-19 Pandemic to Fuel Growth of Intravenous Immunoglobulin Market

The COVID-19 pandemic in its later phase is more likely to propel the growth of the global intravenous immunoglobulin market. December 2020 published article titled, 'COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience', stated that out of 100 individuals with primary immunodeficiency (PID), symptomatic secondary immunodeficiency (SID), autoinflammatory diseases, and C1 inhibitor deficiency, 72% were infected with the SARS-CoV-2 virus and 59% were admitted to hospitals, with 8% admitted to intensive care units. Therefore, an increase in immune-deficient individuals who are at higher risk of being infected with COVID-19 is likely to propel the global intravenous immunoglobulin market during the pandemic.

According to an October 2020 published article titled, 'The uSAGE of Intravenous Immunoglobulin Gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial', the administration of intravenous immunoglobulin in patients with severe COVID-19 infection was expected to enhance the clinical outcome and aid in a significant reduction of the mortality rate due to SARS-CoV2 viral infection. Hence, the global market is likely to witness strong growth during the pandemic.

Analysis of Key Players in Global Intravenous Immunoglobulin Market

This report profiles key players in the global intravenous immunoglobulin market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global intravenous immunoglobulin market is highly fragmented, with the presence of several international as well as regional players. Leading players operating in the global intravenous immunoglobulin market are Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V., among others.

The growing burden of target diseases such as primary immunodeficiency diseases is expected to fuel the growth of the market in the region. According to the National Institute of Allergy and Infectious Diseases, in 2020, more than 400 types of PIDs were diagnosed in the U.S., with more than 500,000 people affected by PIDs.

According to the USIDNET Registry, 2020, the frequency of severe combined immunodeficiency (SCID) among the population of the U.S. stood at 355. Moreover, increase in research & development activities and rapid product approvals are projected to fuel the growth of the intravenous immunoglobulin market growth in North America.

Key Developments in Global Intravenous Immunoglobulin Market

Key players in the global intravenous immunoglobulin market are expanding their market position by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market positions across the world. A few expansion strategies adopted by players operating in the global intravenous immunoglobulin market are:

• In August 2021, Emergent BioSolutions, Inc., a multinational specialty biopharmaceutical company based in the U.S., reported the start of phase III clinical trial to evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (COVID-HIG) plasma-derived therapy as a capable outpatient treatment for patients with coronavirus (COVID-19) who are at high risk of progression to severe disease. Hence, the factors mentioned above are projected to boost the growth of the global intravenous immunoglobulin market during the forecast period.

Some of the prominent players in the Intravenous Immunoglobulin Market include:

• Baxalta Incorporated
• Biotest AG
• China Biologic Products, Inc.
• CSL Behring LLC
• Grifols S.A.
• Kedrion S.p.A.
• LFB Biomedicaments S.A.
• Octapharma AG
• Sanquin Plasma Products B.V.
• Other prominent players

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Intravenous Immunoglobulin market

• Indication
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Primary Humoral Immunodeficiency
• Idiopathic Thrombocytopenic Purpura (ITP)
• Guillain-Barre Syndrome
• Myasthenia Gravis
• Multifocal Motor Neuropathy (MMN)
• Kawasaki Disease
• Hypogammaglobulinemia
• Chronic Lymphocytic Leukemia
• Others
• End-user
• Hospitals
• Clinics
• Home Care

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Intravenous Immunoglobulin industry analysis from 2022 to 2030 to identify the prevailing Intravenous Immunoglobulin industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Intravenous Immunoglobulin industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Intravenous Immunoglobulin industry trends, key players, market segments, application areas, and market growth strategies.